<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022096</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_305</org_study_id>
    <nct_id>NCT04022096</nct_id>
  </id_info>
  <brief_title>Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis</brief_title>
  <official_title>A Phase 3, Double-blind, Randomized, Active-controlled Study to Evaluate the Safety and Efficacy of Tegoprazan as Maintenance Therapy in Patients With Healed Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to confirm the non-inferiority of Tegoprazan 25mg, compared to
      Lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis
      confirmed by endoscopy following oral administration once daily(QD) for 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, active-controlled, phase 3 study. Subjects will be
      randomly assigned to one of the two treatment groups (tegoprazan 25mg, lansoprazole 15mg).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic remission rate of EE at 24-week</measure>
    <time_frame>24-week</time_frame>
    <description>Endoscopic remission: No endoscopic recurrence of erosion(LA grade A to D) during maintenance period(24 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate of EE at 12-week</measure>
    <time_frame>12-week</time_frame>
    <description>Endoscopic remission: No endoscopic recurrence of erosion(LA grades A to D) during maintenance period(12 weeks)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Healed Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 25mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan 25mg tablet, once daily, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 15mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 15mg capsule, once daily, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 25mg QD</intervention_name>
    <description>Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.</description>
    <arm_group_label>Tegoprazan 25mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 15mg QD</intervention_name>
    <description>Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.</description>
    <arm_group_label>Lansoprazole 15mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Erosive eshophagitis(LA classification Grades A to D) within 12 weeks prior to
             Randomization

          2. Healed erosive esophagitis within 7 days prior to Randomization

          3. No heartburn and regurgitation within 7 days prior to Randomization

        Exclusion Criteria:

          1. Unable to undergo upper GI endoscopy

          2. Presence of esophageal stricture, ulcerated stricture, gastroesophageal varix, long
             segment Barrett's esophagus with &gt;3 cm length(LSBE), active digestive ulcer, gastric
             bleeding or malignant tumors on an upper GI endoscopy

          3. Diagnosed with primary esophageal motility disorder, irritable bowel syndome(IBS) or
             inflammatory bowel disease(IBD)

          4. History of acid-suppressive, esophageal or gastric surgeries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oh Young Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University Seoul Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee Hyun Kim</last_name>
    <phone>82-2-6477-0258</phone>
    <email>heehyun.kim@kolmar.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Ja Kang</last_name>
    <phone>82-2-6477-0260</phone>
    <email>minja.kang@kolmar.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 14, 2019</last_update_submitted>
  <last_update_submitted_qc>July 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

